WO2010006476A1 - 心肌肽、其制备方法及用途 - Google Patents
心肌肽、其制备方法及用途 Download PDFInfo
- Publication number
- WO2010006476A1 WO2010006476A1 PCT/CN2008/071647 CN2008071647W WO2010006476A1 WO 2010006476 A1 WO2010006476 A1 WO 2010006476A1 CN 2008071647 W CN2008071647 W CN 2008071647W WO 2010006476 A1 WO2010006476 A1 WO 2010006476A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- amino acid
- gly
- myocardial
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- Cardiomyopeptide preparation method and use thereof
- the present invention relates to polypeptides, in particular two active polypeptides, processes for their preparation and their use. Background technique
- Myocardial protection has been a hot spot in intracardiac and surgical research in recent years. Recent data suggest that many changes occur in ischemic and hypoxic cardiomyocytes, including intracellular calcium overload, free radical production, membrane damage, ATP (adenosine triphosphate) levels, oxygen depletion, and so on.
- the existing various cardiovascular disease treatment drugs do not directly regulate myocardial growth, differentiation, and repair. effect.
- conversion enzyme inhibitors which block growth factor production, inhibit protein synthesis, and alleviate the effect of hypertrophy
- foreign countries have begun to pay attention to the use of drugs to induce the protective ability of the heart muscle itself, such as the study of transduction genes to promote cardiomyocyte regeneration, Cardiotrophin and Myotrophin.
- various mechanisms of transmission are triggered by extracellular signals to regulate the proliferation or remodeling of myocardium and vascular cells. But all of these studies are in animal testing or preclinical research.
- ZL94102798 discloses a cardiomyocyte growth stimulating peptide and a preparation method thereof, and the heart of a healthy young mammal is selected, mechanically mashed, deep frozen at -20 ° C - dissolved and heated at 60-100 ° C, and then -20 ° C Deep-frozen-dissolved and centrifuged at 3000 rpm, and subjected to a negative pressure cut-off column-sterilization-packing-lyophilization-packaging to obtain a polypeptide active material having a molecular weight of less than 20,000 Daltons.
- ZL94102799 discloses a cardiomyocyte growth stimulating peptide (GMGSP) having DNA synthesis and protein synthesis stimulating primary cultured cardiomyocytes, which is prepared from the heart of healthy juvenile mammals and is stable in the range of pH 2-9; Heating at 95-100 ° C for 10 minutes, 60-70 ° C for 30 minutes, the biological activity does not change; in a variety of proteolytic enzymes, 37 ° C 2 hours under the condition of loss of biological activity; in aqueous solution 22 ° C -30 ° C can be The polymer was formed but the biological activity was not changed obviously; under the condition of adding 3%-8% mannitol lyophilized sealing, it was stored at room temperature for 1.5 years, stored at 4 ° C for 2 years, stored at -20 ° C for 3 years, and the biological activity did not change; HPLC analysis showed that the GMGSP consisted of four components, the relative peaks and retention times of each component were: 10.4% (2.88 points), 6.4% (3.93 points), 36.3% (5.09 points
- Each component has biological activity; the two bands shown by SDS-PAGE analysis have a molecular weight of 8500 Da and 10800 Da, respectively, and the number average molecular weight of the HPLC analysis is 9800 Da, and the weight average molecular weight is 10500 Da. Both components have biological activity. .
- the invention discloses that the myocardial peptide is extracted from the heart of a healthy mammal not including human, wherein the content of the polypeptide is 75%-90%, and the free amino acid is 6%- 15%, ribonucleic acid content of 1% -2%, deoxyribonucleic acid content of 3% -7%, weight average molecular weight of 1000-1000 Daltons.
- the invention also discloses the use of the cardiomyopeptide for the preparation of a medicament for treating cardiovascular diseases and for myocardial ischemia and reperfusion injury.
- a method for preparing a myocardial peptide is disclosed in Chinese Patent No.
- 03137133.7 which comprises: washing and chopping ventricular muscles of healthy mammals excluding humans, adding sterilized distilled water homogenate, and repeatedly freezing the homogenate. Thawing 3-4 times, heating to 65-95 °C to filter the slag, filtering with a plate and frame filter to obtain the crude filtrate, ultrafiltration through a hollow fiber column to obtain a fine filtrate, ultrafiltration with ultrafiltration membrane, intercepting the weight average molecular weight
- the myocardial peptide solution of less than 1000OOD is concentrated by a reverse osmosis concentration column, finally sterilized by filtration, and freeze-dried to obtain a finished product.
- the cardiac peptide is extracted from the heart of a healthy mammal that does not include humans, and contains various active ingredients such as a polypeptide, a free amino acid, and a deoxyribonucleic acid.
- a polypeptide is a chain of proteinaceous compounds composed of various amino acids arranged in a different order. Such compounds tend to have strong physiological and functional specificities. Therefore, these polypeptides are widely used in the preparation of drugs for treating certain diseases.
- the present invention aims to provide two polypeptides, wherein the sequence of one polypeptide is: Trp-Ser-Asn-Val-Leu-Arg-Gly-Met-Gly-Gly-Ala-Phe, and the molecular weight is 1294.
- myocardial peptide 75 (abbreviated as myocardial peptide) X);
- myocardial peptide C a new polypeptide (abbreviated as myocardial peptide C) is formed by sequentially connecting alanine, glycine, and lysine to the end to which tryptophan is linked, and the amino acid sequence is: Lys -Gly-Ala-Trp-Ser-Asn-Val-Leu-Arg-Gly-Met-Gly-Gly-Ala-Phe, having a molecular weight of 1550.91.
- the polypeptide is extracted from a myocardial peptide solution, and the polypeptide is determined to be active, and the preparation for treating tissue ischemia includes myocardial ischemia, cerebral ischemia, liver ischemia, gastric ischemia, intestinal ischemia, lung ischemia, Significant use in renal ischemic drugs.
- the technical solution adopted by the present invention is: A polypeptide having an amino acid sequence of: Trp- Ser-Asn-Val-Leu- Arg-Gly-Met-Gly-Gly-Ala-Phe.
- Alanine, glycine, and lysine are sequentially linked to one end of the above polypeptide to which tryptophan is linked to form a novel polypeptide, and the amino acid is arranged in the following order:
- Another object of the present invention is to provide a method for extracting cardiac peptide C.
- a method for extracting myocardial peptide C from a myocardial peptide solution comprising the steps of:
- the active fraction C is subjected to mass spectrometry, and the amino acid sequence of the active peptide in the fraction C is identified by mass spectrometry data analysis, and the fraction C is the polypeptide.
- the ammonium sulfate solution of the present invention has a mass percentage concentration of 60-80%, preferably the concentration is
- the organic solvent described in the step (2) of the present invention is a mixed solution of 60% acetonitrile and 0.1% trifluoroacetic acid.
- the myocardial peptide solution of the present invention comprises extracted from the heart of a healthy mammal that does not include humans.
- the polypeptide solution has a polypeptide content of 75% to 90%, a free amino acid content of 6% to 15%, a ribonucleic acid content of less than 2%, a deoxyribonucleic acid content of less than 7.5 %, a molecular weight of less than 10,000 Daltons, or Existing cardiomyopeptin products.
- a further object of the present invention is to provide a method for chemical synthesis of cardiac peptide C.
- a chemical synthesis method for preparing cardiac peptide C comprising:
- amino group of the amino acid of the step (1) of the present invention may be protected by the following groups:
- each polypeptide or protein is formed by the polymerization of free amino acids through a polypeptide bond.
- the extension of the polypeptide bond always proceeds from the amino terminus (N-terminus) to the carboxy terminus (C-terminus).
- the first amino acid at the carboxy end is usually immobilized on the activated resin, then deprotected by the amino group, and the second amino acid at the carboxy end is added to the opposite In the reactor, the two amino acids are mutually reacted to form a peptide bond, and then the third and fourth amino acids are sequentially added according to the amino acid arrangement sequence of the polypeptide until the last amino acid is bound to the peptide chain.
- Still another object of the present invention is to provide a use of cardiac peptide C for the preparation of a medicament for preventing and/or treating tissue and ischemic agents, preferably for the preparation of a preventive and/or therapeutic myocardial ischemia, cerebral ischemia, hepatic ischemia, stomach
- tissue and ischemic agents preferably for the preparation of a preventive and/or therapeutic myocardial ischemia, cerebral ischemia, hepatic ischemia, stomach
- the use of the polypeptide for the preparation of a medicament for preventing and/or treating myocardial ischemic is more preferred.
- the beneficial effects of the present invention are as follows:
- the present invention discloses a method for extracting two polypeptides, and discloses two polypeptides and sequences contained in a myocardial peptide solution, and completes chemical synthesis, purification, activity determination and identification of the two polypeptides. .
- Activity assays indicate that these two polypeptides are active, and animal studies and clinical studies have shown that these two polypeptides play a significant role in the preparation of drugs for the treatment of myocardial ischemia, cerebral ischemia, and hepatic ischemia. At the same time, these two have the characteristics of clear structure, high activity, easy production, low cost and easier to study and explain their mechanism of action.
- Figure 6 Flow chart of the extraction method of peptide (myocardial peptide C)
- Figure 7 Effect of prophylactic administration of myocardial peptide C on myocardial infarct size in rats with ischemia-reperfusion, Figure 7-a, sham operation group; Figure 7-b is the model group; Figure 7-c is the positive drug group; 7-d is the CMPC group
- Figure 8 Effect of therapeutic administration of myocardial peptide C on myocardial infarct size in rats with ischemia-reperfusion, Figure 8-a, sham operation group; Figure 8-b is the model group; Figure 8-c is the positive drug group; 8-d is the CMPC group
- This example relates to the synthesis of a polypeptide (myocardial peptide C).
- the sequence of the polypeptide is Lys-Gly-Ala-Trp-Ser-Asn-Val-Leu-Arg-Gly-Met-Gly-Gly-Ala-Phe
- the carboxyl group of the second amino acid is activated by HBTU [2-(1H-benzotriazolyl)-1,1,3,3-tetramethylsugaraldehyde-hexafluorophosphate] After neutralization of isopropylethylamine, it is added to the resin in which the first amino acid is bound, and the peptide bond is formed after the two amino acids are reacted.
- the corresponding amino acid is sequentially added, the above washing is repeated, the amino group is deprotected, and the amino acid carboxyl group is activated to carry out 14 peptide reactions, so that the polypeptide chain is continuously extended until the last amino acid is bound to Up to the peptide chain.
- the synthesized polypeptide is still bound to the resin, and the polypeptide substance is separated from the resin by the separation liquid.
- the separation liquid may be a mixture of one or more of phenol, thioanisole and trifluoroacetic acid, and the resin containing the polypeptide ( ⁇ ) is immersed in a 10-80 ml separation solution, and stirred at room temperature.
- the filtrate is then obtained as a mixture of polypeptide materials.
- the free polypeptide material is precipitated by diethyl ether and can be isolated.
- the separated polypeptide substance is dissolved in water or 10-40% alkali solution (alkali can be selected from: ammonium hydrogencarbonate, ammonium carbonate, sodium hydrogencarbonate, sodium carbonate), and then by conventional liquid chromatography,
- alkali can be selected from: ammonium hydrogencarbonate, ammonium carbonate, sodium hydrogencarbonate, sodium carbonate
- the complete polypeptide material is purified.
- the purified polypeptide substance can be measured by ultraviolet spectrophotometry and can be re-verified by mass spectrometry to determine whether the amino acid sequence of the synthesized polypeptide substance is correct.
- This example relates to a method of chemical synthesis of cardiac peptide X.
- the amino acid sequence of the cardiac muscle peptide C is: Trp- Ser-Asn-Val-Leu- Arg-Gly-Met-Gly-Gly-Ala-Phe.
- This example relates to a method of chemical synthesis of cardiac peptide C.
- the method includes the following steps: (1) Deprotection of Fmoc: Take Fmoc-Lys(Boc)-CLTR resin, wash it with dichloromethane for 3 times for 2 min, then drain, add 50% piperidine in dichloromethane at room temperature. 10mL, after 5min reaction, drained, still use the same amount of the above solution for another 30min, then drained, then washed with 8mL ⁇ 10mL of dichloromethane, ethanol and dichloromethane, drained, take a small amount of resin (2mg ⁇ 10 mg) The total amount of amino groups was determined by a free radical method using salicylaldehyde.
- a small amount of the resin was dried to constant weight, and the amount of residual amino groups was determined by a free amino group method using salicylaldehyde, and the condensation ratio was calculated therefrom.
- the degree of progress of the reaction was monitored by ninhydrin coloration, and when the resin was colorless and transparent, it indicated that the condensation reaction was completed.
- step (1) (4) replacing the tree-shaped peptide Fmoc-Lys(Boc)-Wang-R in step (1) with Fmoc-Gly(t-Bu)-Lys(Boc)-R, and Fmoc in step (2) -Gly(t-Bu) is replaced by Fmoc-Ala(Trt), the operations of steps (1) to (3) are repeated, and so on, that is, the resin peptide synthesized in the previous step is used as the amino component of the next synthesis. 14 peptide reactions, all peptide bonds between 15 amino acids are formed;
- This example relates to the synthesis of a polypeptide (myocardial peptide X)
- sequence of the polypeptide is Trp-Ser-Asn-Val-Leu-Arg-Gly-Met-Gly-Gly-Ala-Phe
- This example relates to a method of extracting a polypeptide (myocardial peptide C) from a myocardial peptide solution.
- phase A is 100% H 2 O + 0.1% TFA
- phase B is 60% ACN+ 0.1%
- the active fraction B is concentrated, and then further separated by analytical reversed phase chromatography to collect the active fraction C;
- Phase A is 100% H 2 O + 0.1% TFA
- Phase B is 95% ACN + 0.1% TFA
- This example relates to structural identification and quality detection in the process of extracting a polypeptide (myocardial peptide C) from a myocardial peptide solution.
- the product was subjected to mass spectrometry using a MALDI-TOF-TOF mass spectrometer (AB-4800, USA), in which MALDI-TOF-stage mass spectrometry uses a positive ion reflection detection mode; secondary tandem mass spectrometry uses a positive ion reflection mode, and the detection results are shown in the figure. 2 is shown.
- MALDI-TOF-TOF mass spectrometer AB-4800, USA
- MALDI-TOF-stage mass spectrometry uses a positive ion reflection detection mode
- secondary tandem mass spectrometry uses a positive ion reflection mode
- the activity was measured by the "cardiomyocyte culture activity assay” method provided by Dalian Zhenao Pharmaceutical Co., Ltd. Based on the doxorubicin poisoning test of cardiomyocytes in vitro, this method uses 2, 4-diphenyltetrazolium bromide (MTT) as a reaction indicator to observe the myocardial peptide to enhance the activity of mitochondrial dehydrogenase in damaged cardiomyocytes. The role of to determine myocardial protection.
- MTT 2, 4-diphenyltetrazolium bromide
- CMPC cardiac peptide C
- Cardiac Peptide C supplied by Dalian Zhenao Pharmaceutical Co., Ltd., batch number: C1586102; Verapamil injection (Ver): Shanghai Hefeng Pharmaceutical Co., Ltd., Specification: 2ml: 5mg, batch number: 070701; Doxorubicin (Doxorubicin) for Injection: Guangdong Shantou Special Zone Meiji Pharmaceutical Co., Ltd., Specification: 10mg/bottle, batch number: 070202;
- DMEM medium (high sugar): Gibco, lot number: 1290007;
- DMEM medium low sugar: Gibco, lot number: 1348529;
- Type II collagenase Gibco; fetal bovine serum: Tianjin Haoyang Biological Products Technology Co., Ltd., batch number: 04700701-3100
- SOD superoxide dismutase
- MDA malondialdehyde
- CK creatine kinase
- LDH lactate dehydrogenase
- Glacial acetic acid Tianjin Baishi Chemical Co., Ltd., Specification: 500ml, Batch No.: 20070712; Absolute ethanol: Tianjin Baishi Chemical Co., Ltd., Specification: 500ml, Batch No.: 20070410 II.
- the rat guinea ventricle was taken, D-Hank's was washed and cut, and digested with type II collagenase to obtain myocardial cells and fibroblasts, which were cultured with high glucose DMEM (DMEM-H-15) containing 15% fetal calf serum.
- DMEM-H-15 high glucose DMEM
- the fibroblasts were removed by differential adherence and chemical methods, and the cardiomyocytes were seeded into 96-well plates.
- the cell culture method is the same as 1. 1.
- Model preparation Experimental control group: Cardiomyocytes were cultured with DMEM-H-15; Model group: Add 1 mg/L doxorubicin, culture for 1 h, wash plate twice with DMEM-H-15, add DMEM-H -15 culture; positive control group (Verapamil 2, 0.4, 0.08 mg / L) and different concentrations of test drug group (CMPC 50, 10, 2, 0.4, 0.08, 0.016, 0.0032, 0.00064 mg / L): The cardiomyocytes damaged by doxorubicin for 1 h were washed twice with DMEM-H-15 and then added to each concentration of verapamil injection (Ver) and CMPC (the total volume of each group was 100 ⁇ /well, The drug concentration refers to the final concentration).
- Cardiomyocyte culture method is the same as 1.1.
- Model preparation The model of cardiomyocytes cultured for 48-72 h was prepared, and the cells in each well of the culture plate were divided into control group, model group, verapamil group (2, 0.4, 0.08 mg/L final concentration) and CMPC group ( The final concentration was 50, 10, 2, 0.4, 0.08, 0.016, 0.0032 mg/L), and each group was 3 duplicate wells. Except for the control group, the other cells were prepared as follows: After replacing the cardiomyocyte monolayer in the culture plate with low-sugar medium (containing the corresponding concentration of verapamil or CMPC), the plate was placed in a vacuum desiccator.
- CMPC can significantly improve the survival rate of cardiomyocytes.
- the protective effect is better when the drug concentration is 0.08-2 mg/L, which is significantly different from the model group.
- 3 CMPC EC 5 were 0.66, 0.14, and 0.82 mg/L, respectively.
- the results are shown in Table 2 (protection rate of CMPC for cardiomyocytes is expressed as "%").
- a total of 70 SD rats of 250-300 g were taken, and 60 of them were randomly divided into 6 groups according to body weight, 10 in each group, and the remaining 10 were used to supplement each group of dead animals.
- Normal control group sham operation, that is, a line of left anterior descending coronary artery (LAD) was worn, but no ligation;
- Model group intravenous injection of saline 5 ml/kg 30 min before ligation, ischemia-reperfusion operation See model preparation for details.
- Positive drug group intravenous infusion of verapamil 1.0 mg/kg 30 min before ligation, ischemia-reperfusion operation with model group;
- CMPC high, medium and low dose groups intravenous infusion of corresponding concentration of CMPC 30 min before ligation ( 1.8, 0.6, 0.2 mg/kg), ischemia-reperfusion operation Same model group.
- Model preparation After anesthetized with 6% urethane solution in a 20 ml/kg intraperitoneal injection, the animal was placed in the supine position on the operating table; connected to an electrocardiograph, limb II electrocardiogram; tracheal intubation, animal respirator According to the tidal volume of 6ml/200g and the frequency of 55 times/min, continuous positive pressure ventilation was given at the end of expiration, and the respiratory ratio was 2:1. Open the thoracic surgery at the fourth/five intercostal space on the left sternal border. After removing the pericardium from the ribs, the lower atrial appendage is used as a marker.
- the 6/0 silk thread is used to connect the left anterior descending coronary artery, and the ligature is placed between the ligature and the blood vessel.
- Reperfusion was successful by a 1/2 or more decrease in reactive hyperemia and elevation of the S-T segment in the ischemic zone. After reperfusion for 30 min, blood was taken from the abdominal aorta, and serum was prepared for determination of biochemical indicators (determination of CK, LDH, MDA, SOD content according to the kit instructions).
- the rat heart was dissected, and the blood in the heart chamber was washed with physiological saline. The whole heart was weighed, the fat was removed, and 4-5 pieces of the myocardium were placed in a test tube, and NBT staining was performed at 37 ° C (normal tissue). Staining, ischemic tissue is not stained), photographed. The ischemic myocardium was weighed and the myocardial infarct size (MIS) was calculated as the percentage of ischemic myocardium weight and total wet weight.
- MIS myocardial infarct size
- Serum CK and LDH were significantly increased in the model group (PO.01).
- the positive drug group significantly decreased serum CK and LDH activities (P ⁇ 0.05).
- the CMPC high-dose group and the CMPC medium-dose group were significantly more significant than the model group.
- the serum LDH activity of rats was decreased (P ⁇ 0.05).
- the high dose group of CMPC and the medium dose group of CMPC could significantly reduce CK activity (P ⁇ 0.05).
- the low dose group of CMPC could decrease the activity of LDH and CK, but there was no significant difference. (P>0.05).
- the results are shown in Table 3.
- the serum SOD activity of the model group was significantly decreased (P ⁇ 0.01), and the MDA value was significantly increased (PO.01).
- the positive drug Ver could significantly increase the serum SOD activity (P ⁇ 0.01) and reduce the MDA activity (PO.05).
- the CMPC-H, M, L dose groups significantly increased serum SOD activity in coronary artery ligation rats (P ⁇ 0.01, P ⁇ 0.05) and decreased MDA content (P ⁇ 0.01, P ⁇ 0.05). The results are shown in Table 4.
- the myocardial infarct size of the model group was significantly increased (P ⁇ 0.01).
- the positive drug group and CMPC prophylactic drug group compared with the model group could significantly reduce the myocardial infarct size (P ⁇ 0.01).
- Table 5 and Figure 7. Table 5 Effect of prophylactic administration of myocardial peptide C on myocardial infarct size in rats with ischemia-reperfusion ( ⁇ : ⁇ SD)
- CMPC myocardial ischemia-reperfusion injury in rats
- the LAD was ligated 5 minutes after ligation, and LAD was ligated for 30 min. After 30 min of reperfusion, the abdominal aorta was harvested and the heart was dissected. The biochemical parameters and myocardial infarct size were measured by the same method.
- Serum CK and LDH were significantly increased in the model group (PO.01).
- the positive drug Ver significantly decreased serum CK and LDH activities (P ⁇ 0.05, P ⁇ 0.01).
- the CMPC-H and M dose groups were compared with the model group.
- the activity of CK and LDH in serum was significantly decreased (P ⁇ 0.01, P ⁇ 0.05).
- CMPC-L could decrease the activity of LDH and CK, but there was no significant difference (P>0.05). The results are shown in Table 6.
- the serum SOD activity of the model group was significantly decreased (P ⁇ 0.05), and the MDA value was significantly increased (PO.01).
- the positive drug Ver could significantly increase the serum SOD activity (P ⁇ 0.05) and reduce the MDA content (PO.05).
- CMPC-H and M could significantly increase serum SOD activity (P ⁇ 0.05, P ⁇ 0.01), and CMPC-L increased SOD activity, but there was no significant difference compared with the model group. >0.05); DMC-H, M, L dose groups can reduce MDA content (P ⁇ 0.05), the results are shown in Table 7.
- Table 7 Effect of therapeutic administration of myocardial peptide C on serum SOD and MDA in rats with ischemia-reperfusion ( ⁇ : ⁇ SD)
- the myocardial infarct size of the model group was significantly increased (P ⁇ 0.01).
- the positive drug Ver and CMPC therapeutic groups were significantly lower than the model group (P ⁇ 0.05).
- the results are shown in Table 8, Figure 8.
- Table 8 Effect of therapeutic administration of myocardial peptide C on myocardial infarct size in rats with ischemia-reperfusion ( ⁇ : ⁇ SD)
- myocardial peptide C can increase the activity of mitochondrial dehydrogenase in injured cardiomyocytes, and has a protective effect on injured cardiomyocytes.
- myocardial peptide c prophylactic and therapeutic administration can significantly reduce serum CK, LDH, MDA levels in ischemia-reperfusion rats, significantly increase SOD content, and in a dose-dependent manner, and can reduce rat myocardial Infarct size, indicating that myocardial peptide C therapeutic and prophylactic administration have protective effects on myocardial ischemia-reperfusion injury in rats.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011517731A JP5373077B2 (ja) | 2008-07-15 | 2008-07-15 | ポリペプチド系物質、その製造方法、組織器官の虚血の予防用薬及び治療用薬 |
EP08773191.5A EP2314600B1 (en) | 2008-07-15 | 2008-07-15 | Myocardial peptide, preparation method and uses thereof |
US13/054,229 US8940865B2 (en) | 2008-07-15 | 2008-07-15 | Myocardial peptide, preparation method and uses thereof |
PCT/CN2008/071647 WO2010006476A1 (zh) | 2008-07-15 | 2008-07-15 | 心肌肽、其制备方法及用途 |
KR1020117003285A KR101505239B1 (ko) | 2008-07-15 | 2008-07-15 | 심근 펩타이드, 이의 제조방법 및 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2008/071647 WO2010006476A1 (zh) | 2008-07-15 | 2008-07-15 | 心肌肽、其制备方法及用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010006476A1 true WO2010006476A1 (zh) | 2010-01-21 |
Family
ID=41549989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2008/071647 WO2010006476A1 (zh) | 2008-07-15 | 2008-07-15 | 心肌肽、其制备方法及用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8940865B2 (zh) |
EP (1) | EP2314600B1 (zh) |
JP (1) | JP5373077B2 (zh) |
KR (1) | KR101505239B1 (zh) |
WO (1) | WO2010006476A1 (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1065129C (zh) * | 1994-03-15 | 2001-05-02 | 中国人民解放军第458医院 | 利心康 |
CN1552439A (zh) * | 2003-06-04 | 2004-12-08 | 大连珍奥药业有限公司 | 心肌肽素及其用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7000898A (en) * | 1996-11-01 | 1998-05-29 | Emory University | Mouse lacking heart-muscle adenine nucleotide translocator protein and methods |
EP1783221A1 (en) * | 2000-05-11 | 2007-05-09 | MIGENIX Corp. | Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
DK1661907T3 (da) * | 2003-06-04 | 2012-05-07 | Dalian Zhen Ao Pharmaceutical Co Ltd | Fremgangsmåde til fremstilling af cardiomyopeptidin |
-
2008
- 2008-07-15 JP JP2011517731A patent/JP5373077B2/ja not_active Expired - Fee Related
- 2008-07-15 EP EP08773191.5A patent/EP2314600B1/en not_active Not-in-force
- 2008-07-15 KR KR1020117003285A patent/KR101505239B1/ko active IP Right Grant
- 2008-07-15 WO PCT/CN2008/071647 patent/WO2010006476A1/zh active Application Filing
- 2008-07-15 US US13/054,229 patent/US8940865B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1065129C (zh) * | 1994-03-15 | 2001-05-02 | 中国人民解放军第458医院 | 利心康 |
CN1552439A (zh) * | 2003-06-04 | 2004-12-08 | 大连珍奥药业有限公司 | 心肌肽素及其用途 |
Non-Patent Citations (2)
Title |
---|
LI, R. B. ET AL.: "Therapeutic effect of cardiomyopeptidin on rat cardiac ischemia -reperfusion injury", CHINESE JOURNAL OF PATHOPHYSIOLOGY, vol. 18, no. 5, 2002, pages 556 - 557, XP008141760 * |
See also references of EP2314600A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP2314600A4 (en) | 2012-04-25 |
JP2011527991A (ja) | 2011-11-10 |
JP5373077B2 (ja) | 2013-12-18 |
KR20110045000A (ko) | 2011-05-03 |
KR101505239B1 (ko) | 2015-03-23 |
US20110160432A1 (en) | 2011-06-30 |
EP2314600A1 (en) | 2011-04-27 |
US8940865B2 (en) | 2015-01-27 |
EP2314600B1 (en) | 2017-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1976948A (zh) | 修饰的Exendins及其应用 | |
JP2819467B2 (ja) | 新規なカルジオジラチン断片およびその製造方法 | |
AU2017234460A1 (en) | Multi-functional fusion polypeptide, preparation method thereof, and application of same | |
JPH0729925B2 (ja) | 新生物形成病用医薬組成物 | |
JP2625156B2 (ja) | 細胞接着活性コア配列の繰り返し構造からなるポリペプチド | |
JPS60184098A (ja) | 新規なペプチド及びこれを有効成分とする利尿剤 | |
CA2405704C (en) | Bombesin analogs for treatment of cancer | |
WO2022148289A1 (zh) | 一类用于修复皮肤损伤或黏膜损伤的多肽及其应用 | |
CN101265292B (zh) | 多肽类物质、其制备方法及其用途 | |
WO2010006476A1 (zh) | 心肌肽、其制备方法及用途 | |
WO2007054030A1 (fr) | Modifications polyethylene glycole de thymosine alpha-1 | |
US6921749B1 (en) | Polypeptides derived from endostatin exhibiting antiangiogenic activity | |
CN102304178B (zh) | 光滑爪蟾抗肿瘤多肽制备方法及用途 | |
CN116801896A (zh) | Bl-8040的组合物 | |
JP3728494B2 (ja) | 新規な血清コレステロール低下ペプチド | |
CN109280079A (zh) | 一种蛙来源的创伤修复肽及其合成方法 | |
CZ20032612A3 (cs) | HeterokarpinŹ proteinŹ který váže lidský GHRH | |
CN103012555A (zh) | 具有组织保护活性的新多肽的制备方法及在治疗中的应用 | |
JP3723838B2 (ja) | 新規な抗脱毛ペプチド | |
CN116768974A (zh) | 用于预防和/或治疗肾纤维化的多肽化合物 | |
CN106554405B (zh) | 一种多肽及其用途、制备方法 | |
US6989371B1 (en) | Bombesin analogs for treatment of cancer | |
CN117257915A (zh) | 一种红细胞搭便车偶联物及其制备方法和应用 | |
JP2617700B2 (ja) | 細胞接着活性コア配列の繰り返し構造からなるポリペプチド | |
DK171969B1 (da) | Tetrapeptid, dets fremstilling og anvendelse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08773191 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2011517731 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2008773191 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008773191 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117003285 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13054229 Country of ref document: US |